Nakabayashi,
Hajime, Makoto Nishizawa, Atsushi Nakagawa, Ryoyu Takeda, and Akira Niijima. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am. J. Physiol. 271 (Endocrinol.
Metab. 34): E808-E813, 1996.-Among proglucagon-derived peptides, the truncated form of glucagon-like peptide-1, GLP-1( 7-36)amide (tGLP-I), is known as the most likely physiological humoral incretin.
To examine whether there exists any relationship between tGLP-1 levels in th .e portal vein and activities of the hepatic an .d pancreati c vagal system, changes of the impulse discharge rate in the hepatic afferent vagus and the pancreatic efferent vagus upon intraportal tGLP-1 injection were measured in situ in rats anesthetized with urethan and chloralose. First, a 1-min bolus tGLP-1 injection at a periphysiological dose of 0.2 pmol or a pharmacological dose of 4.0 pmol, but not the vehicle injection, significantly facilitated the hepatic vagal afferents for >90 min, showing weaker facilitation at the 0.05 pmol dose. Notably, the injection of noninsulinotropic full-length GLP-1 failed to facilitate the afferents at the 4.0 or 40.0 pmol dose. Second, the intraportal tGLP-1 injections at the 0.05 and 0.2 pmol dose facilitated marginally and significantly the pancreatic vagal efferents in normal rats, respectively, but had no effect on the hepatic vagotomized rats, even at the 40.0 pmol dose. The present results indicate that an intraportal appearance of tGLP-1 is specifically recognized by the hepatic vagal nerve, and this recognition further augments the pancreatic vagal efferent activity in a reflex way, suggesting another nature of tGLP-1 as neuroincretin in the enteroinsular axis.
vagal hormone reception; proglucagon-derived peptide; portal vein; enteroinsular axis; rat; truncated glucagon-like peptide-1 AN INCREASE IN PLASMA insulin level in response to Oral glucose administration is much greater than that to intravenous glucose administration, where plasma glucose levels are equivalent in both routes of glucose administration (see review in Ref. 5 ). This gut-derived insulinotropic effect, named enteroinsular axis (31), has been attributed to humoral and neural factors operating on ingestion of glucose or a mixed meal (5). As for the gut-derived peptide hormones, glucagon-like peptide-1-( l-37) (GLP-1) and its truncated form, amide (tGLP-l), are produced through posttranslational processing of proglucagon in the intestinal endocrine L cells (27) . tGLP-1 is released into the circulation as a predominant truncated form of GLP-1 in response to absorption of glucose and fatty acids (4, 28) . Moreover, because tGLP-1, but not full-length GLP-1, has a powerful insulinotropic activity (12, 15>, tGLP-1 has been claimed as one of the physiological candidates in the enteroinsular axis (13,28,32).
Concerning the proglucagon-derived peptides existing outside the intestine (see review in Ref. 8), identification and localization of GLP-l-like immunoreactivity and of tGLP-1 in the central nervous system have been reported, showing their high concentrations in the hypothalamus where the autonomic functions are regulated. Expression of high-affinity receptor for tGLP-1 in rat brain has also been reported (8, 9), suggesting that tGLP-1 is a gut-brain peptide. However, little is known of existence of either tGLP-1 or its receptor in the peripheral autonomic nervous system.
In the present study, we aimed to examine whether there exists any relationship between levels of circulating tGLP-1 and functions of the hepatic and pancreatic vagal system, viewing the role(s) of tGLP-1 as neural and/or humoral incretin from a new perspective. First, we have examined whether tGLP-1 administered into the portal vein at a physiological dose changes the afferent activity of the hepatic vagal nerve in normal rats. Second, we have studied how the intraportal tGLP-1 administration modifies the efferent activity of the pancreatic vagal nerve in normal and hepatic vagotomized rats. The present results clearly indicate that the hepatic vagal nerve recognizes an intraportal appearance of tGLP-1, and this recognition further leads to facilitation of the pancreatic vagal efferent activity in a reflex way. The results suggest that tGLP-1 plays a role as neuroincretin in the enteroinsular axis, in concert with its role as humoral incretin.
MATERIALS AND METHODS
After 14-16 h of fasting, male Wistar rats (250-300 g) were anesthetized by intraperitoneal injection of a mixture of urethan (720 mg/kg) and oc-chloralose (65 mg/kg). The trachea was intubated, and an electrocardiogram was recorded in each rat. After laparotomy, a small tubing (Intramedic PE-10; Clay Adams, Parsippany, NJ) was inserted into the portal vein, through which tGLP-1, GLP-1, or the vehicle was injected. tGLP-1 or GLP-1 was dissolved in physiological saline solution containing 0.5% bovine serum albumin were gifts of Dr. K. Kawai, Tsukuba University, Tsukuba, Japan (30)]. tGLP-l was injected into the portal vein at a dose of 0.05, 0.2, or 4.0 pmol, which was assumed to be a physiological, a periphysiological, or a pharmacological dose by calculation, respectively (see DISCUS-SION) .
GLP-1 at a dose of 4.0 or 40.0 pmol, or the vehicle as a control, was also administered intraportally.
The volume of solution injected in each experiment was 200 ul, and duration of the injection was 60 s.
Afferent activity of the hepatic vagus was expressed as the firing spike discharge rate in the nerve in which afferent fibers were known to distribute to the hepatoportal area and to be located terminally in the portal adventitia (1). The discharge rate was measured in the nerve filaments isolated GLP-1 AND VAGAL HEPATOPANCREATIC REFLEX PATHWAYS E809 from the hepatic vagal branch under a dissection microscope (X 16 magnification). The distal cut end of the nerve filaments was placed on a pair of silver wire electrodes and was immersed in a mixture of liquid paraffin and Vaseline. To measure efferent activity in the pancreatic vagal nerve, the proximal cut end of the isolated nerve filaments from the pancreatic branch of the dorsal vagal trunk was used in a manner mentioned above in the afferent activity measurement, as previously described (17, 18) . In the hepatic vagotomized rats, the hepatic branch of the vagal nerve was 30 msec -selectively sectioned just before preparing the pancreatic nerve filaments.
The nerve activity was amplified by a condenser-coupled differential amplifier, monitored by an oscilloscope, and stored on magnetic tape. Analysis of the nerve activities was performed after conversion of raw data to standard pulses by a window discriminator, which distinguished impulse discharges of the afferent or efferent fibers a b from background noise. The discharge rate was played on a thermal recorder or an oscilloscope by a rate meter with a 100 reset time of 5 s to establish the time course. The injection of 8 0 tGLP-1, GLP-1, or the vehicle was started after a stable basal z discharge rate over at least 30 min in each rat had been G 30 min confirmed. To calculate the mean discharge rate, the number + B I
of spikes per 5 s was averaged over 50 s. The techniques U J ml -employed had been described elsewhere (17, 18, 25) g 100 The results were expressed as means t SE. Two-way -analysis of variance followed by Scheffe's multiple compari-0 son test for comparing time course data within a group and two-way repeated-measures analysis of variance for compar-30 min ing variables between groups were employed. Values of P < normal rats. Injection of tGLP-1 at a periphysiological vs. the value before injection, n = 6). Intraportal dose of 0.2 pmol into the portal vein provoked an increase of the afferent spike discharge rate in the injection of tGLP-1 at a pharmacological dose of 4.0 hepatic vagal nerve, not changing the mean amplitude of the spikes in the time course. The increase started within a few minutes after injection and usually lasted for >90 min after injection (Fig. 1 ). As shown in Fig. 2A , the spike discharge rate significantly rose from 67 t 4 impulses/5 s before injection to 109 t 12, 137 t 17, and 145 5 13 at 30, 60, and 90 min after injection, respectively (P < 0.05 at 30 min and P < 0.01 at 60 and 90 min By contrast, intraportal administration of full-length GLP-1 at a dose of 4.0 pmol did not significantly change charge rate as shown in Fig. 20 (n = 6). the discharge rate, although the discharge rate tended to increase slightly in the time course (n = 5, Fig. 2C ).
Effect of intraportal administration of tGLP-1 or Moreover, even 40.0 pmol GLP-1 again did not induce any significant change of the discharge rate (n = 4, data not shown). These GLP-l-induced changes of the discharge rates were not significantly different from those induced by the vehicle administration, which also induced a slight but insignificant increase in the discharge rate from 66 2 4 impulses/5 s before injection to 99 t 5, 114 2 7, and 120 2 10 at 30, 60, and 90 min pmol also induced a significant increase of the disnormal and hepatic vagotomized rats. Injection of tGLP-1 at a dose of 0.2 pmol into the portal vein caused vehicle on efferek activity of the pancreatic vagus in after injection, respectively (P < 0.01 at all time points vs. the value before injection, n = 7, Fig. 2B ). The increases with 4.0 pmol injection were not significantly an increase in the efferent spike discharge rate of the pancreatic mean amp vagus in n itude of the .ormal spikes rats, not changing in the time course.
the The different from those with 0.2 pmol injection at any time increase started within a few minutes after injection point.
and usually lasted for >90 min afterwards (Fig. 3) . As To further determine a minimum effective dose of shown in Fig. 4 , the discharge rate in the pancreatic tGLP-1 in eliciting significant rise of the afferent vagus significantly increased from 62 2 6 impulses/5 s discharge rate, 0.05 pmol of tGLP-1 were injected into before injection to 127 t 19, 142 ? 16, and 159 t 17 at the portal vein in five rats. The tGLP-1 administration 30, 60, and 90 min after injection, respectively (P < induced a small and rather short-lasting increase (for 0.01 at all time points vs. the value before injection, n = 45-60 min) in the activity in three out of five rats tested 6). Furthermore, when tGLP-1 of 0.05 pmol, which was and induced no change in the others (data not shown).
a minimally effective dose in facilitating the hepatic vagal afferents as noted above, was injected into the (13) and in patients with non-insulin-dependent diabeportal vein, the pancreatic efferents showed a small tes mellitus (NIDDM; see Ref. 24) . However, the preand short-lasting increase for -60 min in three out of sent electrophysiological results clearly indicate that six rats tested but showed no change in the others (data an appearance of tGLP-1, but not of full-length GLP-1, not shown).
into the portal vein facilitates the afferent activity in In hepatic vagotomized rats, however, intraportal the hepatic vagal nerve. The results also indicate that injection of 0.2 pmol tGLP-1 did not induce significant hepatic afferent activity that is facilitated leads further changes of the pancreatic efferent discharge rate (n = 5, to facilitation of the efferent activity in the pancreatic Figs. 3 and 4) , showing apparently smaller changes vagus, revealing a novel vagal hepatopancreatic reflex than those in normal rats at all time points (P < 0.05). pathway. These results suggest that tGLP-1 released Moreover, injection of even 40.0 pmol, 200-fold dose, into the portal vein upon meal ingestion also behaves tGLP-1 also failed to facilitate the efferents (n = 4, data as neuroincretin in the enteroinsular axis. not shown). The responses of the efferents to both doses
The hepatic vagus seems to be very sensitive in of tGLP-1 in the vagotomized rats were not signifirecognizing an intraportal appearance of tGLP-1. As to cantly different from those to the vehicle in normal rats plasma tGLP-1 levels, it has been reported that tGLP-1 or hepatic vagotomized rats (n = 4 in each, data not 1 evels shown).
in the peripheral venous plasma increase from l-10 pmol./l to 20-50 in response to ingestion of a DISCUSSION As most likely physiological candidates for humoral incretin, tGLP-1 (13, 28, 32) and glucose-dependent insulinotropic polypeptide (also known as gastric inhibitory polypeptide; see Refs. 6, 23) have been listed to date. In fact, both peptides are released into the circulation in response to ingestion of glucose, fatty acids, and a mixed meal, and both stimulate insulin secretion in a physiological range of their plasma concentrations (6, 13, 23, 28, 32). Action of tGLP-1 as incretin has particularly been noted in normal subjects mixed meal or glucose in humans (7, 13, 29) and that the levels in postprandial arterial plasma are -20 pmol/l in rat (32), using different assays among laboratories. Because intraportal tGLP-1 levels observed in a physiological situation such as meal ingestion have not been reported previously in rats and knowing its levels is prerequisite for evaluating the sensitivity in the vagal recognition, we attempted to obtain the portal blood samples in conscious rats but hardly succeeded. Alternatively, we assumed by calculation that intraportal tGLP-1 administration at a dose of 0.2 or 4.0 pmol achieves systemic tGLP-1 levels within a periphysiologi- cal or a pharmacological range, respectively, in a previous report (32). In this case, actual systemic tGLP-1 levels seem to become lower than those expected in the intraportal administrations, since the liver extracts tGLP-1 to some extent. Besides, the intraportal administration of tGLP-1, even at a dose as small as 0.05 pmol, has elicited some increases of the hepatic vagal afferent activity (data not shown). This stresses that the vagal recognition system is exquisitely sensitive to tGLP-1. Taken together, it is conceivable that the maximal response to tGLP-1 would already be evident at a supposed periphysiological dose of 0.2 pmol, because the dose of 4.0 pmol induced no further augmented responses.
This recognition system for tGLP-1 in the hepatoportal area is very specific as well as sensitive. Intraportal administration of full-length GLP-1 known to have no incretin effect did not change significantly the afferent activity of the hepatic vagus, even at a dose of as large as 40.0 pmol, showing a slight but insignificant increase in the time course that is similar to an unexplained and insignificant change in the present vehicle administration.
The results indicate that the vagal recognition system can distinguish NH2-terminal difference of only six amino acids between tGLP-1 and GLP-I-( l-37),
suggesting an involvement of specific receptor for tGLP-1 in the recognition. In this regard, we have recently obtained a line of unique evidence for vagal chemoreception to another brain-gut hormone, somatostatin, in the hepatoportal area (16, 18, 19) . First, the hepatic vagus is receptive to somatostatin circulating in the portal vein (18,119). The receptivity to somatostatin is completely abolished with a monoclonal antibody against somatostatin receptor that binds to the binding site of the receptor (19, 21) . The results strongly suggest that the reception of somatostatin is mediated by the specific receptor system. Second, as the relevant histological structure in the chemoreception to somatostatin, we have further discovered the neural bodies that are located beneath the endothelium of the large branches of the intrahepatic portal vein in rat and that preferentially trap somatostatin (18; the neural body had been termed as the neural corpuscle in Ref. 18) . Each neural body contained many nerve fiber arborizations with terminal nodular swellings like the afferent nerve endings in its core (16, 18) . Moreover, when the neural body is immunostained with the monoclonal antibody to somatostatin receptor, presence of the receptor on the terminal tip of the nerve fiber arborizations was clearly visualized (16). By analogy of these electrophysiological and histological evidence on the specific receptor-mediated chemoreception of somatostatin, we can hypothesize that a specific receptor system for tGLP-1 could also be involved in the present observation, by which humoral information (circulating tGLP-1) is converted to neural information. As to tGLP-1 receptor in the liver, it has been reported that the specific receptor is not present either on hepatocytes or in rat liver membranes (Z), but the tGLP-1 receptor mRNA is present in the liver of the mice (3). It is thus intriguing whether tGLP-1 receptor is present in the nervous system associated with the portal vein in the liver, particularly on the nerve fiber arborizations within the neural bodies, as observed in the case of somatostatin reception (18). The time course of tGLP-l-induced changes of the afferent discharge rate in the hepatic vagus is noteworthy; the vagal afferent activity started to increase within a few minutes after tGLP-1 injection and lasted for >90 min, even after the 1-min bolus injection. This time course seems to represent a characteristic feature of the vagal chemoreception, which involves a specific receptor system for a peptide hormone secreted from the splanchnic organs, since a similar electrophysiological event was also observed in the neural chemoreception of somatostatin (18, 19) . This vagal reception of somatostatin was completely canceled when the monoclonal antibody to somatostatin receptor was administered intraportally before intraportal somatostatin injection (19) . By contrast, the reception was evident without any modification when the antibody was administered after somatostatin injection (19). This shows that the afferent activity, once stimulated by the hormone, cannot be hampered any more by modulating the ligand binding to the receptor with the antibody. These observations suggest that a unique postreceptor mechanism is involved in the reception and that the mechanism offers a base for explaining the long-lasting effect of somatostatin (probably also of tGLP-1) on the afferent discharge rate. At the same time, the observation on this unique postreceptor mechanism implies that the receptor-mediated reception might have a nature suitable for detecting an initial increase in intraportal concentrations of both of these hormones raised usually for 3-4 h after a mixed meal. It may also be relevant to this hypothesis that an additional administration of a larger dose of somatostatin in the increasing phase of the pancreatic vagal afferent activity induced by somatostatin failed to stimulate further increases (17 (22) and even in diabetic patients lacking endogenous insulin secretion (10). The effect in the postprandial state was also reported in normal rats (11). However, an underlying mechanism(s) involved in tGLP-l-induced reduction of postprandial glucose excursion is not clarified in the previous reports (10, 11, 22) . The present reflex pathway triggered by an intraportal appearance of tGLP-1 might be relevant to the mechanism(s).
The signal arisen from the vagal tGLP-1 reception in the hepatoportal area may diverge onto the splanchnic organs via the vagal and/or the sympathetic nerve as the efferent limb(s) of the reflex pathways.
In fact, it has been reported that an intraportal appearance of glucose attenuates the hepatic vagal afferent activity (25) and further leads to divergent efferent events such as stimulation of the pancreatic vagal activity and suppression of the activities in the gastric vagus and the adrenal sympathetic nerve (26). In addition to our previous observation on the somatostatin-induced facilitation of the hepatic vagal afferents (18, 19>, we have recently observed that intraportal somatostatin administration causes suppression of the small intestinal vagal efferents and facilitation of the efferents in the intestinal sympathetic nerve in rats (unpublished observation). These results seem to be pertinent to our previous observation, which showed that an intraportal somatostatin administration suppressed the entry of fat from the intestine to blood circulation under intact, but not under disrupted, vagal (extrinsic) innervation in dogs (20). Thus it is tempting to speculate that the efferent parasympathetic and/or sympathetic limbs of the present reflex pathway triggered by intraportal tGLP-1 appearance reach the stomach, liver, and muscle. If so, tGLP-1 might change gastric emptying, hepatic glucose metabolism, and insulin-independent glucose disposal, and these factors might be relevant to the tGLP-l-induced reduction of postprandial glucose excursion observed clinically. Finally, the present results will provide a new insight into the role of tGLP-1 in the enteroinsular axis,
